PETS

PetMed Express Inc. (PETS) - Q1 2025 (Ended June 30, 2024) Summary

Business Context and Reporting Period

PetMed Express, Inc. is a leading direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, and veterinary services. The company operates primarily through its websites (PetMeds.com and PetCareRx.com). This report covers the first quarter of fiscal year 2025, ended June 30, 2024. The company's fiscal year ends on March 31.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Sales decreased 13.2% year-over-year to $67.95 million. Reorder sales dropped 11.8% due to declines in prescription medication sales, while new order sales fell 28.4% attributed to reduced gross media spend and fewer new customer acquisitions (75,000 vs. 86,000).
• Profitability Turnaround: The company reported a net income of $3.75 million compared to a net loss of $1.14 million in the prior year. This improvement was primarily driven by a significant reduction in stock-based compensation expense.
• Stock Compensation Reversal: General and administrative expenses decreased 69.0% to $4.87 million. This was largely due to an $8.7 million reversal of compensation expense resulting from the cancellation of performance restricted shares for the former CEO upon his departure.
• Cash Flow Deterioration: Operating cash flow turned negative, using $8.52 million compared to providing $0.56 million in the prior year. This was driven by a $12.6 million decrease in accounts payable and a $3.0 million reduction in inventory, offset by the non-cash stock compensation reversal.
• Dividend Suspension: The company suspended its quarterly dividend indefinitely in October 2023 to focus cash flow on growth initiatives. No dividends were declared in Q1 2025.

Guidance, Outlook, Risks, and Unusual Items

• Restatement: The company restated financial results for the three months ended June 30, 2023, to correct material misstatements regarding sales tax accruals and the valuation of deferred tax assets related to the PetCareRx acquisition.
• Internal Control Weaknesses: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses in tax accounting controls and IT general controls (user access and change management). A remediation plan is underway.
• Legal Proceedings: A class-action lawsuit was filed in April 2024 alleging violations of Pennsylvania's Unfair Trade Practices and Consumer Protection Law regarding "reg." pricing. The company denies liability and cannot estimate potential damages at this time.
• Outlook: Management cites macroeconomic factors, inflation, and increased competition as challenges. They expect these factors to continue impacting revenue growth rates for the remainder of fiscal 2025.
• Adjusted EBITDA: Adjusted EBITDA was negative $1.54 million for the quarter, a significant decline from $3.34 million in the prior year, reflecting the impact of the revenue decline and the non-recurring nature of the stock compensation reversal.

Investor Verification Checklist

• Restatement Impact: Verify the full extent of the restatement on prior periods and the specific adjustments made to sales tax liabilities and deferred tax assets.
• Internal Control Remediation: Monitor the progress of the remediation plan for material weaknesses in tax accounting and IT general controls to ensure future financial reporting reliability.
• Revenue Drivers: Assess the sustainability of the decline in reorder sales and the effectiveness of new marketing strategies to reverse the drop in new customer acquisition.
• Legal Exposure: Track the status of the Pennsylvania class-action lawsuit regarding pricing practices and potential liability.
• Cash Burn: Review the trend in operating cash flow, specifically the reduction in accounts payable and inventory, to ensure liquidity remains sufficient for operations without debt.